Clinical trials: Obesity Overweight
Pulmonary Disease, Chronic Obstructive, Amyotrophic Lateral Sclerosis
European Home Mechanical Ventilation Registry
The European Home Mechanical Ventilation Registry (EHMVR) will enable a thorough evaluation of HMV by documenting the characteristics of HMV patients and their treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, Muscular Dystrophies
- Trial name
- EHMVR (NCT02315339)
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- ResMed
Overweight and Obesity
An Evaluation of Omega-3 Fatty Acid
This protocol will determine the pK profile of two different omega-3 fatty acid supplements on plasma EPA and DHA levels.
- Trial name
- NCT03017651
- Testing
- OM3-supplement 1, OM3-supplement 2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity, Type 2 Diabetes
MagDI Australia Study
The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Trial name
- NCT06473831
- Testing
- Magnet System, DI Biofragmentable
- Where
- 4 sites in Australia
- Volunteers
- 25 people
- Sponsor
- GT Metabolic Solutions, Inc.
Obesity
Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific
ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product.
- Trial name
- ACTION-APAC (NCT05250427)
- Testing
- No treatment given
- Where
- 9 sites in Bangladesh, India and 7 more
- Volunteers
- 12,404 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.
The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2.
- Trial name
- NCT07121153
- Testing
- NNC0487-0111 A
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Overweight
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and ambulatory blood pressure in obese participants.
- Trial name
- NCT01749137
- Testing
- Setmelanotide
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Healthy
A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)
Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection.
- Trial name
- NCT07748351
- Testing
- MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), MK-4082 Formulation 4 (F4)
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overweight and Obesity
Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers
Overweight and obesity is defined, according to the World Health Organization (WHO), by abnormal or excessive accumulation of adipose or fatty tissue that may be harmful to health.
- Trial name
- NCT03685656
- Testing
- Slimming gel
- Where
- France
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Nutravalia
Overweight, Obesity
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy)…
- Trial name
- NCT00444561
- Testing
- pramlintide acetate
- Where
- 10 sites in United States
- Volunteers
- 184 people
- Sponsor
- AstraZeneca
Diabetes type2, Obesity
The RESET System Pivotal Clinical Trial (Protocol Revision K)
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.
- Trial name
- STEP-1 (NCT04101669)
- Testing
- RESET Liner
- Where
- 27 sites in United States
- Volunteers
- 264 people
- Sponsor
- Morphic Medical Inc.
Obesity
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1…
- Trial name
- NCT01235741
- Testing
- Pramlintide+Metreleptin
- Where
- 18 sites in United States
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Overweight, Obesity
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing
The study is testing a new study medicine called NNC0487-0111 for weight control in Chinese people with Body mass index (BMI) greater than or equal to (>=) 24 kilogram per square meter (kg/m^2).
- Trial name
- NCT06820476
- Testing
- NNC0487-0111
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Obesity
Crave Crush Behavioral Study
The purpose of the research is to determine if participants who take "Crave Crush" will report lower cravings and palatability ratings of candy as compared to subjects who receive the placebo.
- Trial name
- NCT02744885
- Testing
- Crave Crush
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Obesity and Type 2 Diabetes
BMS-646256 in Obese and Overweight Type 2 Diabetics
This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2…
- Trial name
- NCT00541567
- Testing
- ibipinabant
- Volunteers
- 600 people
- Sponsor
- Solvay Pharmaceuticals
Overweight and Obese Volunteers.
Efficacy and Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers
The prevalence of overweight and obesity is getting more and more important in developed as well as in emerging countries. It can be defined according to the degree of fat storage by measurement of fat mass.
- Trial name
- NCT02246699
- Testing
- KiOnutrime®-Cs
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Kitozyme
Obesity
A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects
The ReShape Post Approval Study is a prospective multicenter study of the ReShape(TM) Integrated Dual Balloon System in Obese Subjects.
- Trial name
- ReShapePAS (NCT02927665)
- Testing
- Reshape Integrated Dual Balloon
- Where
- 14 sites in United States
- Volunteers
- 186 people
- Sponsor
- ReShape Lifesciences
Type 2 Diabetes, Obese
The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes
The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on glycemic control and weight in overweight and obese adults with Prediabetes or Type 2…
- Conditions
- Type 2 Diabetes, Obese, Overweight, Prediabetes
- Trial name
- NCT05844644
- Testing
- Release
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Golo
Obesity
A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program
The purpose of this study is to compare the efficacy and safety of topiramate 96mg and 192mg daily) with placebo in the treatment of obesity following an intensive non-pharmacologic weight loss program.
- Trial name
- NCT00236600
- Testing
- topiramate
- Volunteers
- 561 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Part A: Healthy Part B: Overweight or Obesity
A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and…
- Trial name
- NCT07160400
- Testing
- IBI3032 tablets
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Overweight, Obesity
A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity, but it has been approved as a…
- Trial name
- NCT04187300
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.